Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates

Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20:153–214.

Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Meth. 2000;44:235–49.

Jiskoot W, van Schie RM, Carstens MG, Schellekens H. Immunological risk of injectable drug delivery systems. Pharm Res. 2009;26:1303–14.

Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006;8:E572–9.

Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457–62.

Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98:2909–34.

Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4:298–306.

Philo JS. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol. 2009;10:359–72.

Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98:1201–5.

Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2004;57:369–75.

Brown PH, Schuck P. Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J. 2006;90:4651–61.

Fraunhofer W, Winter G, Coester C. Asymmetrical flow field-flow fractionation and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems. Anal Chem. 2004;76:1909–20.

Frisken BJ. Revisiting the method of cumulants for the analysis of dynamic light-scattering data. Appl Opt. 2001;40:4087–91.

Demeester J, Smedt S, Sanders N, Haustraete J. Light Scattering. In: Jiskoot W, Crommelin DJ, editors. Methods for structural analysis of protein pharmaceuticals. Arlington: AAPS; 2005.

Berne B, Pecora R. Dynamic light scattering with applications to chemistry, biology, and physics. Mineola: Dover; 2000.

Applications of Nanoparticle Tracking Analysis (NTA) in Nanoparticle Research. http://www.schaefer-tec.com/fileadmin/user_upload/sortiment/nanopartikel/NanoSight/NANOSIGHT_Application_Review_NTA_April_2009_M201B.pdf (accessed 26/09/2009), part of NanoSight. http://www.nanosight.co.uk (accessed 26/09/2009).

Slutter B, Plapied L, Fievez V, Sande MA, des Rieux A, Schneider YJ, et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release. 2009;138:113–21.

Minimum DLS concentration? http://www.malvern.com/malvern/kbase.nsf/allfaqbyno/KB000795?opendocument (accessed 22/09/2009), part of Malvern support FAQ. http://www.malvern.com (accessed 22/09/2009).

Can DLS resolve oligomer mixtures? http://www.malvern.com/malvern/kbase.nsf/allfaqbyno/KB001102 (accessed 22/09/2009), part of Malvern support FAQ. http://www.malvern.com (accessed 22/09/2009).

Mahler HC, Muller R, Friess W, Delille A, Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm. 2005;59:407–17.

Kaszuba M, McKnight D, Connah MT, McNeil-Watson FK, Nobbmann U. Measuring sub nanometre sizes using dynamic light scattering. J Nanopart Res. 2007;10:823–9.

Hvidt S. Insulin association in neutral solutions studied by light scattering. Biophys Chemist. 1991;39:205–13.

Bee JS, Stevenson JL, Mehta B, Svitel J, Pollastrini J, Platz R, et al. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng. 2009;103:936–43.